GeneFerm Biotechnology Co., Ltd.
1796
Rank in Stocks
#24306
GeneFerm Biotechnology Co., Ltd. specializes in the development, production,... GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line includes a variety of microbial fermentation offerings such as different types of mushrooms, lactic acid bacteria, other bacterial strains, yeast, and algae. Furthermore, GeneFerm provides a wide array of bio-fermented ingredients, including specialized powders like nattomena, natto fermented powder, red yeast rice fermented powder, and various mycelial powders (e.g., antrodia cinnamomea, cordyceps, reishi, phellinus linteus, armillaria mellea). They also supply beta-glucan powder, fermented fruit and vegetable enzymes, as well as probiotic and peptide components. Beyond its product sales, GeneFerm offers additional services such as private label supplement manufacturing, packaging equipment, and expert microbial fermentation toll manufacturing and consulting. Established in 1988, the company maintains its headquarters in Tainan City, Taiwan.
Share Price
$0.82460461
Last synced: 2026-11-10
Market Cap
$34.19M
Change (1 day)
0.56%
Change (1 year)
-47.84%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GeneFerm Biotechnology Co., Ltd. (1796)
Category
Healthcare
EPS for GeneFerm Biotechnology Co., Ltd. (1796)
EPS as of June 2026 TTM: $0.01
According to GeneFerm Biotechnology Co., Ltd.'s latest financial reports, its current EPS (TTM) is $0.01. At the end of 2025 the company had an EPS of $0.02, an increase over its 2024 EPS of $-0.02.
EPS history for GeneFerm Biotechnology Co., Ltd. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.01 | -36.50% |
| 2025 | $0.02 | -235.15% |
| 2024 | $-0.02 | -116.82% |
| 2023 | $0.10 | 33.11% |
| 2022 | $0.07 | 40.92% |
| 2021 | $0.05 | 817.54% |
| 2020 | $0.01 | -117.22% |
| 2019 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 51,092.13% |
DE
|
|
| $6.08 | 47,755.12% |
DE
|
|
| $1.55 | 12,109.45% |
JP
|
|
| $3.66 | 28,718.90% |
CH
|
|
| $0.45 | 3,443.31% |
IL
|
Questions about GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS)
What is GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS)?
GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) over the last twelve months is $0.01, as of Jun 2026.
What was GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) in 2025?
In 2025, GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) was $0.02, compared with $-0.02 in 2024.
How has GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) went from $0.01 to $0.02, an average growth of 14.87% a year.
How does GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) compare with similar companies?
GeneFerm Biotechnology Co., Ltd.'s earnings per share (EPS) ($0.01) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.